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To the Editor
Apparent comorbidity between bipo-
lar disorder (BD) and anxiety disor-
ders is a common condition in 
psychiatry with a lifetime prevalence 
of comorbid anxiety disorders in BD 
patients of 45% and higher prevalence 
rates for generalized anxiety disorder 
and social phobia.
One of the most difficult additional 
diagnoses to manage in BD patients is 
obsessive–compulsive disorder (OCD; 
Tonna et al. 2015), since the gold 
standard for one disease (serotonin 
reuptake inhibitors for OCD) can 
worsen the other (Amerio et al., 2014).
We present the case of a patient 
with severe OCD who developed a 
manic episode during treatment with 
citalopram. The patient is a 32-year-old 
Caucasian man with positive family his-
tory for recurrent depression. From 
the age of 21 years, he had presented 
recurrent, intrusive, ego-dystonic 
thoughts having sexual and aggressive 
content that led him to compulsive 
mental acts (specifically, praying). These 
symptoms met Diagnostic and Statistical 
Manual of Mental Disorders, 4th edition, 
criteria for OCD. No history of manic 
or depressive episodes was reported.
He was admitted to the inpatient 
service and treated with citalopram 
60 mg/day with satisfactory control of 
obsessive–compulsive (OC) symp-
toms. After 3 months on citalopram 
60 mg/day, he developed a manic epi-
sode. His therapy was modified to val-
proate 800 mg/day and olanzapine 
20 mg/day. Olanzapine was gradually 
decreased, and valproate was contin-
ued with remission of OC symptoms 
and mood stabilization.
After 8 months, he decided to stop 
valproate and compulsive rituals 
increased prominently. Citalopram 
20 mg/day was added to valproate 
with improvement of OC symptoms 
and mood stabilization.
In our case, positive family history 
for recurrent depression, manic switch 
induced by antidepressant and 
improvement of affective and OC 
symptoms with mood stabilizers and 
atypical antipsychotics support the 
hypothesis of an underlying bipolarity.
Considering course of illness as a 
key diagnostic validator, the majority 
of comorbid OCD cases appeared to 
be related to mood episodes (Amerio 
et al., 2015). OC symptoms appeared 
more often during depressive epi-
sodes, and comorbid BD and OCD 
cycled together, with OC symptoms 
often remitting during manic or hypo-
manic episodes.
BD-OCD clinical features would 
explain why these patients respond to 
adequate mood stabilizer treatment 
(Amerio et al., 2014). Only in a minor-
ity of comorbid patients with persis-
tent OCD, despite improvement in 
mood episodes, addition of low doses 
of antidepressants could be considered 
while strictly monitoring emerging 
symptoms of mania or mixed states.
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To the Editor
The prevalence of severe obesity is 
increasing in Australasia, and bariatric 
surgery offers the most effective long-
term treatment for this condition.
A recent case report in this Journal 
described the onset of mania follow-
ing bariatric surgery (Hamdani et al., 
2015) highlighting the relevance of 
this area for psychiatrists. Here, we 
report the onset of a severe alcohol 
use disorder (AUD) after bariatric 
surgery in a woman with no prior his-
tory of heavy drinking.
A 55-year-old female health pro-
fessional was referred for psychiatric 
assessment before resuming work, 
having been abstinent from alcohol 
for 3 months while attending daily 
Alcoholics Anonymous meetings.
Seven years earlier her body mass 
index was 40, and she underwent 
Roux-en-Y gastric bypass surgery 
(RYGB). The surgery was successful, 
and the patient’s body mass index fell 
to 32 within 12 months.
The patient had a lifetime history of 
consuming less than 20 g alcohol per 
week before surgery. She had never 
smoked or used illicit substances, but 
she described eating compulsively to 
alleviate stress and boredom. Her 
mother and a brother were heavy 
drinkers, and a maternal uncle had fatal 
complications of chronic alcoholism.
Twelve months after surgery, the 
patient received a promotion, which 
she found stressful. She began con-
suming up to 4 bottles of wine per 
day. Her relationships and work suf-
fered. Over the next 2 years, she 
developed a severe relapsing AUD. 
She lost her professional practising 
certificate and required 6 months in 
residential alcohol treatment.
An increased incidence of AUDs 
following bariatric surgery has 
recently been reported; risk factors 
include being male, younger, a tobacco 
smoker or recreational substance 
user, having low social support and 
undergoing RYGB rather than laparo-
scopic banding (King et al., 2012; 
Suzuki et al., 2012).
We suggest measuring eating com-
pulsivity and eliciting a family history of 
addictive behaviours might also help 
identify patients at risk of AUD follow-
ing bariatric surgery. Patients should 
be advised prior to surgery about the 
risk of AUD. Finally, patients may be 
more at risk in the second year after 
surgery (King et al., 2012), highlighting 
the need for monitoring beyond the 
initial postoperative period. Mental 
health clinicians should play a role in 
this monitoring since much of the 
morbidity following bariatric surgery is 
psychiatric rather than surgical.
Declaration of Conflicting 
Interests
The author(s) declared no potential con-
flicts of interest with respect to the 
research, authorship and/or publication of 
this article.
Funding
The author(s) received no financial sup-
port for the research, authorship and/or 
publication of this article.
References
Hamdani N, Boukouaci W, Hallouche MR, et al. 
(2015) Resolution of a manic episode treated 
with activated charcoal: Evidence for a brain–
gut axis in bipolar disorder. Australian and New 
Zealand Journal of Psychiatry 49: 1221–1223.
King WC, Chen J, Mitchell JE, et al. (2012) 
Prevalence of alcohol use disorders before 
and after bariatric surgery. Journal of the 
American Medical Association 307: 2516–2525.
Suzuki J, Haimovici F and Chang G (2012) Alcohol 
use disorders after bariatric surgery. Obesity 
Surgery 22: 201–207.
Natural weight loss 
supplements – Are they 
psychoactive?
Michael Beecheno, Silver Budd 
and Titus Mohan
Flinders Medical Centre, Australia
Corresponding author:
Titus Mohan, Flinders Medical Centre, 
Margaret Tobin Centre, Adelaide, SA 5042, 
Australia. 
Email: titus.mohan@health.sa.gov.au
DOI: 10.1177/0004867416634869
To the Editor
Weight loss substitutes are advertised 
as quick solutions to the ever-expanding 
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